Curcumin use in pulmonary diseases: State of the art and future perspectives

Pharmacological Research

Volumn 115, Issue , 2017, Pages 133-148

  Lelli, Diana ^a   Sahebkar, Amirhossein ^b   Johnston, Thomas P ^c   Pedone, Claudio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Curcumin; Cystic fibrosis; Lung; Pulmonary fibrosis

Indexed keywords

CURCUMIN; CXCL2 CHEMOKINE; CYCLOOXYGENASE 2; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINE; DNA; DOCETAXEL; ERLOTINIB; GEFITINIB; GELATINASE A; GELATINASE B; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ACUTE LUNG INJURY; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ASTHMA; CANCER INHIBITION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DOWN REGULATION; DRUG DNA BINDING; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; ANIMAL; INFLAMMATION;

ANIMALS; CURCUMIN; HUMANS; INFLAMMATION; LUNG DISEASES;

EID: 84999187799     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.11.017     Document Type: Review

References (201)

1. [1] Shishodia, S., Sethi, G., Aggarwal, B.B., Curcumin: getting back to the roots. Ann. N. Y. Acad. Sci. 1056 (2005), 206–217, 10.1196/annals.1352.010.
2. [2] Aggarwal, B.B., Sundaram, C., Malani, N., Ichikawa, H., Curcumin: the indian solid gold. Aggarwal, B.B., Surh, Y.-J., Shishodia, S., (eds.) Mol. Targets Ther. Uses Curcumin Health Dis., 2007, Springer, US, 1–75, 10.1007/978-0-387-46401-5_1.
3. [3] Cheng, A.L., Hsu, C.H., Lin, J.K., Hsu, M.M., Ho, Y.F., Shen, T.S., Ko, J.Y., Lin, J.T., Lin, B.R., Ming-Shiang, W., Yu, H.S., Jee, S.H., Chen, G.S., Chen, T.M., Chen, C.A., Lai, M.K., Pu, Y.S., Pan, M.H., Wang, Y.J., Tsai, C.C., Hsieh, C.Y., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21 (2001), 2895–2900.
4. [4] Aggarwal, B.B., Harikumar, K.B., Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 41 (2009), 40–59, 10.1016/j.biocel.2008.06.010.
5. [5] Bagdonas, E., Raudoniute, J., Bruzauskaite, I., Aldonyte, R., Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 10 (2015), 995–1013, 10.2147/COPD.S82518.
6. [6] Cohn, L., Elias, J.A., Chupp, G.L., Asthma: mechanisms of disease persistence and progression. Annu. Rev. Immunol. 22 (2004), 789–815, 10.1146/annurev.immunol.22.012703.104716.
7. [7] Wilson, M.S., Wynn, T.A., Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2 (2009), 103–121, 10.1038/mi.2008.85.
8. [8] Tyagi, N., Kumari, A., Dash, D., Singh, R., Protective effects of intranasal curcumin on paraquot induced acute lung injury (ALI) in mice. Environ. Toxicol. Pharmacol. 38 (2014), 913–921, 10.1016/j.etap.2014.10.003.
9. [9] Xu, F., Diao, R., Liu, J., Kang, Y., Wang, X., Shi, L., Curcumin attenuates staphylococcus aureus-induced acute lung injury. Clin. Respir. J. 9 (2015), 87–97, 10.1111/crj.12113.
10. [10] Baldwin, A.S., Series Introduction: the transcription factor NF-κB and human disease. J. Clin. Invest. 107 (2001), 3–6.
11. [11] Aggarwal, S., Ichikawa, H., Takada, Y., Sandur, S.K., Shishodia, S., Aggarwal, B.B., Curcumin (Diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and akt activation. Mol. Pharmacol. 69 (2006), 195–206, 10.1124/mol.105.017400.
12. [12] Menon, V.P., Sudheer, A.R., Antioxidant and anti-inflammatory properties of curcumin. Aggarwal, B.B., Surh, Y.-J., Shishodia, S., (eds.) Mol. Targets Ther. Uses Curcumin Health Dis., 2007, Springer, US, 105–125, 10.1007/978-0-387-46401-5_3.
13. [13] Takahashi, M., Ishiko, T., Kamohara, H., Hidaka, H., Ikeda, O., Ogawa, M., Baba, H., Curcumin 7-bis(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3,5-dione) blocks the chemotaxis of neutrophils by inhibiting signal transduction through IL-8 receptors. Mediators Inflamm., 2007, 2007, 1, 10.1155/2007/10767.
14. [14] Sharma, S., Chopra, K., Kulkarni, S.K., Agrewala, J.N., Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin. Exp. Immunol. 147 (2007), 155–163, 10.1111/j.136 -2249.2006.03257.x.
15. [15] Douglas, D.E., 4,4′-Diacetyl curcumin?in-vitro histamine-blocking activity. J. Pharm. Pharmacol., 45, 1993, 766.
16. [16] Ito, K., Adcock, I.M., Histone acetylation and histone deacetylation. Mol. Biotechnol. 20 (2002), 99–106, 10.1385/MB:20:1:099.
17. [17] Meja, K.K., Rajendrasozhan, S., Adenuga, D., Biswas, S.K., Sundar, I.K., Spooner, G., Marwick, J.A., Chakravarty, P., Fletcher, D., Whittaker, P., Megson, I.L., Kirkham, P.A., Rahman, I., Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am. J. Respir. Cell Mol. Biol. 39 (2008), 312–323, 10.1165/rcmb.2008-0012OC.
18. [18] Joe, B., Lokesh, B.R., Role of capsaicin, curcumin and dietary n–3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim. Biophys. Acta BBA—Mol. Cell Res. 1224 (1994), 255–263, 10.1016/0167-4889(94)90198-8.
19. [19] Strasser, E.-M., Wessner, B., Manhart, N., Roth, E., The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells. Biochem. Pharmacol. 70 (2005), 552–559, 10.1016/j.bcp.2005.05.030.
20. [20] Biswas, S., Hwang, J.W., Kirkham, P.A., Rahman, I., Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. Curr. Med. Chem. 20 (2013), 1496–1530.
21. [21] Suzuki, M., Betsuyaku, T., Ito, Y., Nagai, K., Nasuhara, Y., Kaga, K., Kondo, S., Nishimura, M., Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 39 (2008), 673–682, 10.1165/rcmb.2007-0424OC.
22. [22] Balogun, E., Hoque, M., Gong, P., Killeen, E., Green, C.J., Foresti, R., Alam, J., Motterlini, R., Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 371 (2003), 887–895, 10.1042/BJ20021619.
23. [23] Morse, D., Choi, A.M.K., Heme oxygenase-1. Am. J. Respir. Cell Mol. Biol. 27 (2002), 8–16, 10.1165/ajrcmb.27.1.4862.
24. [24] Haines, D.D., Lekli, I., Teissier, P., Bak, I., Tosaki, A., Role of haeme oxygenase-1 in resolution of oxidative stress-related pathologies: focus on cardiovascular, lung, neurological and kidney disorders. Acta Physiol. Oxf. Engl. 204 (2012), 487–501, 10.1111/j.1748 -1716.2011.02387.x.
25. [25] Kumar, D., Kumar, M., Saravanan, C., Singh, S.K., Curcumin: a potential candidate for matrix metalloproteinase inhibitors. Expert Opin. Ther. Targets 16 (2012), 959–972, 10.1517/14728222.2012.710603.
26. [26] Hu, Y., Peng, J., Feng, D., Chu, L., Li, X., Jin, Z., Lin, Z., Zeng, Q., Role of extracellular signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-beta1-induced alpha smooth muscle actin expression in human fetal lung fibroblasts in vitro. Lung 184 (2006), 33–42, 10.1007/s00408-005-2560-5.
27. [27] Zhang, D., Huang, C., Yang, C., Liu, R.J., Wang, J., Niu, J., Brömme, D., Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts. Respir. Res., 12, 2011, 154, 10.1186/1465-9921-12-154.
28. [28] Mehta, H.J., Patel, V., Sadikot, R.T., Curcumin and lung cancer—a review. Target. Oncol. 9 (2014), 295–310, 10.1007/s11523-014-0321-1.
29. [29] Shishodia, S., Amin, H.M., Lai, R., Aggarwal, B.B., Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 70 (2005), 700–713, 10.1016/j.bcp.2005.04.043.
30. [30] Huang, T.S., Lee, S.C., Lin, J.K., Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 5292–5296.
31. [31] Pendurthi, U.R., Rao, L.V., Suppression of transcription factor Egr-1 by curcumin. Thromb. Res. 97 (2000), 179–189.
32. [32] Park, M.-J., Kim, E.-H., Park, I.-C., Lee, H.-C., Woo, S.-H., Lee, J.-Y., Hong, Y.-J., Rhee, C.H., Choi, S.-H., Shim, B.-S., Lee, S.-H., Hong, S.-I., Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor p21WAF1/CIP1, p27KIP1 and p53. Int. J. Oncol. 21 (2002), 379–383.
33. [33] Wilken, R., Veena, M.S., Wang, M.B., Srivatsan, E.S., Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer., 10, 2011, 12, 10.1186/1476-4598-10-12.
34. [34] Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 4 (2007), 807–818, 10.1021/mp700113r.
35. [35] Anand, P., Thomas, S.G., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Sung, B., Tharakan, S.T., Misra, K., Priyadarsini, I.K., Rajasekharan, K.N., Aggarwal, B.B., Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem. Pharmacol. 76 (2008), 1590–1611, 10.1016/j.bcp.2008.08.008.
36. [36] Awasthi, S., Pandya, U., Singhal, S.S., Lin, J.T., Thiviyanathan, V., Seifert, W.E., Awasthi, Y.C., Ansari, G.A., Curcumin-glutathione interactions and the role of human glutathione S-transferase P 1-1. Chem. Biol. Interact. 128 (2000), 19–38.
37. [37] Iersel, M.L., Ploemen, J.P., Struik, I., van Amersfoort, C., Keyzer, A.E., Schefferlie, J.G., van Bladeren, P.J., Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem. Biol. Interact. 102 (1996), 117–132.
38. [38] Gupta, S.C., Prasad, S., Kim, J.H., Patchva, S., Webb, L.J., Priyadarsini, I.K., Aggarwal, B.B., Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep. 28 (2011), 1937–1955, 10.1039/c1np00051a.
39. [39] Jung, Y., Xu, W., Kim, H., Ha, N., Neckers, L., Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. Biochim. Biophys. Acta 1773 (2007), 383–390, 10.1016/j.bbamcr.2006.11.004.
40. [40] Sharma, R.A., Gescher, A.J., Steward, W.P., Curcumin: the story so far. Eur. J. Cancer Oxf. Engl. 1990 41 (2005), 1955–1968, 10.1016/j.ejca.2005.05.009.
41. [41] Hatcher, H., Planalp, R., Cho, J., Torti, F.M., Torti, S.V., Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. CMLS 65 (2008), 1631–1652, 10.1007/s00018-008-7452-4.
42. [42] Bera, R., Sahoo, B.K., Ghosh, K.S., Dasgupta, S., Studies on the interaction of isoxazolcurcumin with calf thymus DNA. Int. J. Biol. Macromol. 42 (2008), 14–21, 10.1016/j.ijbiomac.2007.08.010.
43. [43] Nafisi, S., Adelzadeh, M., Norouzi, Z., Sarbolouki, M.N., Curcumin binding to DNA and RNA. DNA Cell Biol. 28 (2009), 201–208, 10.1089/dna.2008.0840.
44. [44] Zsila, F., Bikadi, Z., Simonyi, M., Circular dichroism spectroscopic studies reveal pH dependent binding of curcumin in the minor groove of natural and synthetic nucleic acids. Org. Biomol. Chem. 2 (2004), 2902–2910, 10.1039/B409724F.
45. [45] Barry, J., Fritz, M., Brender, J.R., Smith, P.E.S., Lee, D.-K., Ramamoorthy, A., Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. J. Am. Chem. Soc. 131 (2009), 4490–4498, 10.1021/ja809217u.
46. [46] Ingolfsson, H.I., Koeppe, R.E., Andersen, O.S., Curcumin is a modulator of bilayer material properties. Biochemistry (Mosc.) 46 (2007), 10384–10391, 10.1021/bi701013n.
47. [47] Baum, L., Ng, A., Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. JAD., 6, 2004 (367–377–449).
48. [48] Mohammadi, K., Thompson, K.H., Patrick, B.O., Storr, T., Martins, C., Polishchuk, E., Yuen, V.G., McNeill, J.H., Orvig, C., Synthesis and characterization of dual function vanadyl, gallium and indium curcumin complexes for medicinal applications. J. Inorg. Biochem. 99 (2005), 2217–2225, 10.1016/j.jinorgbio.2005.08.001.
49. [49] Thompson, K.H., Böhmerle, K., Polishchuk, E., Martins, C., Toleikis, P., Tse, J., Yuen, V., McNeill, J.H., Orvig, C., Complementary inhibition of synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a vanadyl curcumin complex compared to curcumin alone. J. Inorg. Biochem. 98 (2004), 2063–2070, 10.1016/j.jinorgbio.2004.09.011.
50. [50] Lou, J.R., Zhang, X.-X., Zheng, J., Ding, W.-Q., Transient metals enhance cytotoxicity of curcumin: potential involvement of the NF-kappaB and mTOR signaling pathways. Anticancer Res. 30 (2010), 3249–3255.
51. [51] Salvi, S.S., Barnes, P.J., Chronic obstructive pulmonary disease in non-smokers. Lancet 374 (2009), 733–743, 10.1016/S0140-6736(09)61303-9.
52. [52] Forbes, L.J.L., Kapetanakis, V., Rudnicka, A.R., Cook, D.G., Bush, T., Stedman, J.R., Whincup, P.H., Strachan, D.P., Anderson, H.R., Chronic exposure to outdoor air pollution and lung function in adults. Thorax 64 (2009), 657–663, 10.1136/thx.2008.109389.
53. [53] Overbeek, S.A., Braber, S., Koelink, P.J., Henricks, P.A., Mortaz, E., LoTam Loi, A.T., Jackson, P.L., Garssen, J., Wagenaar, G.T.M., Timens, W., Koenderman, L., Blalock, J.E., Kraneveld, A.D., Folkerts, G., Cigarette smoke-Induced collagen destruction; key to chronic neutrophilic airway inflammation?. PLoS One, 8, 2013, 10.1371/journal.pone.0055612.
54. [54] Kobayashi, S.D., DeLeo, F.R., Towards a comprehensive understanding of the role of neutrophils in innate immunity: a systems biology-level approach. Wiley Interdiscip. Rev. Syst. Biol. Med. 1 (2009), 309–333, 10.1002/wsbm.32.
55. [55] Stefano, A.D., Caramori, G., Oates, T., Capelli, A., Lusuardi, M., Gnemmi, I., Ioli, F., Chung, K.F., Donner, C.F., Barnes, P.J., Adcock, I.M., Increased expression of nuclear factor-(B in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 20 (2002), 556–563, 10.1183/09031936.02.00272002.
56. [56] Walters, M.J., Paul-Clark, M.J., McMaster, S.K., Ito, K., Adcock, I.M., Mitchell, J.A., Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance. Mol. Pharmacol. 68 (2005), 1343–1353, 10.1124/mol.105.012591.
57. [57] Barnes, P.J., Shapiro, S.D., Pauwels, R.A., Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J. 22 (2003), 672–688, 10.1183/09031936.03.00040703.
58. [58] Russell, R.E.K., Thorley, A., Culpitt, S.V., Dodd, S., Donnelly, L.E., Demattos, C., Fitzgerald, M., Barnes, P.J., Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am. J. Physiol. Lung Cell. Mol. Physiol. 283 (2002), L867–L873, 10.1152/ajplung.00020.2002.
59. [59] Majo, J., Ghezzo, H., Cosio, M.G., Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur. Respir. J. 17 (2001), 946–953.
60. [60] Cosio, M.G., Majo, J., Cosio, M.G., Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 121 (2002), 160S–165S.
61. [61] Barnes, P.J., Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 71 (2009), 451–464, 10.1146/annurev.physiol.010908.163257.
62. [62] R.T. Abboud, S. Vimalanathan, Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema [State of the Art Series. Chronic obstructive pulmonary disease in high- and low-income countries. Edited by G. Marks and M. Chan-Yeung. Number 3 in the series], Int. J. Tuberc. Lung Dis. 12 (2008) 361–367.
63. [63] Braber, S., Koelink, P.J., Henricks, P.A.J., Jackson, P.L., Nijkamp, F.P., Garssen, J., Kraneveld, A.D., Blalock, J.E., Folkerts, G., Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am. J. Physiol. Lung Cell. Mol. Physiol. 300 (2011), L255–L265, 10.1152/ajplung.00304.2010.
64. [64] Mui, T.S.Y., Man, J.M., McElhaney, J.E., Sandford, A.J., Coxson, H.O., Birmingham, C.L., Li, Y., Man, S.F.P., Sin, D.D., Telomere length and chronic obstructive pulmonary disease: evidence of accelerated aging. J. Am. Geriatr. Soc. 57 (2009), 2372–2374, 10.1111/j.1532-5415.2009.02589.x.
65. [65] Fujii, S., Hara, H., Araya, J., Takasaka, N., Kojima, J., Ito, S., Minagawa, S., Yumino, Y., Ishikawa, T., Numata, T., Kawaishi, M., Hirano, J., Odaka, M., Morikawa, T., Nishimura, S., Nakayama, K., Kuwano, K., Insufficient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary disease. Oncoimmunology 1 (2012), 630–641, 10.4161/onci.20297.
66. [66] Ng, T.P., Niti, M., Yap, K.B., Tan, W.C., Curcumins-rich curry diet and pulmonary function in Asian older adults. PLoS One, 7, 2012, e51753, 10.1371/journal.pone.0051753.
67. [67] Panahi, Y., Ghanei, M., Hajhashemi, A., Sahebkar, A., Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. J. Diet. Suppl. 13 (2016), 93–105, 10.3109/19390211.2014.952865.
68. [68] Biswas, S.K., McClure, D., Jimenez, L.A., Megson, I.L., Rahman, I., Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. Antioxid. Redox Signal. 7 (2005), 32–41, 10.1089/ars.2005.7.32.
69. [69] Kalpana, C., Menon, V.P., Curcumin ameliorates oxidative stress during nicotine-induced lung toxicity in Wistar rats. Ital. J. Biochem. 53 (2004), 82–86.
70. [70] Moghaddam, S.J., Barta, P., Mirabolfathinejad, S.G., Ammar-Aouchiche, Z., Garza, N.T., Vo, T.T., Newman, R.A., Aggarwal, B.B., Evans, C.M., Tuvim, M.J., Lotan, R., Dickey, B.F., Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Carcinogenesis 30 (2009), 1949–1956, 10.1093/carcin/bgp229.
71. [71] Kang, J., Chen, J., Shi, Y., Jia, J., Zhang, Y., Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem. Pharmacol. 69 (2005), 1205–1213, 10.1016/j.bcp.2005.01.014.
72. [72] Panahi, Y., Ghanei, M., Bashiri, S., Hajihashemi, A., Sahebkar, A., Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res. 65 (2015), 567–573, 10.1055/s-0034-1389986.
73. [73] Elias, J.A., Lee, C.G., Zheng, T., Ma, B., Homer, R.J., Zhu, Z., New insights into the pathogenesis of asthma. J. Clin. Invest. 111 (2003), 291–297, 10.1172/JCI17748.
74. [74] Wills-Karp, M., Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17 (1999), 255–281, 10.1146/annurev.immunol.17.1.255.
75. [75] Tschumperlin, D.J., Shively, J.D., Kikuchi, T., Drazen, J.M., Mechanical stress triggers selective release of fibrotic mediators from bronchial epithelium. Am. J. Respir. Cell Mol. Biol. 28 (2003), 142–149, 10.1165/rcmb.2002-0121OC.
76. [76] Robinson, D.S., Hamid, Q., Ying, S., Tsicopoulos, A., Barkans, J., Bentley, A.M., Corrigan, C., Durham, S.R., Kay, A.B., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326 (1992), 298–304, 10.1056/NEJM199201303260504.
77. [77] Davies, R.J., Wang, J.H., Trigg, C.J., Devalia, J.L., Expression of granulocyte/macrophage-colony-stimulating factor, interleukin-8 and RANTES in the bronchial epithelium of mild asthmatics is down-regulated by inhaled beclomethasone dipropionate. Int. Arch. Allergy Immunol. 107 (1995), 428–429.
78. [78] Shi, H.Z., Humbles, A., Gerard, C., Jin, Z., Weller, P.F., Lymph node trafficking and antigen presentation by endobronchial eosinophils. J. Clin. Invest. 105 (2000), 945–953, 10.1172/JCI8945.
79. [79] Atkinson, J.J., Senior, R.M., Matrix metalloproteinase-9 in lung remodeling. Am. J. Respir. Cell Mol. Biol. 28 (2003), 12–24, 10.1165/rcmb.2002-0166TR.
80. [80] Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z., Shimizu, J., Takahashi, T., Nomura, T., Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 2006, 8–27, 10.1111/j.0105-2896.2006.00427.x.
81. [81] Oh, S.-W., Cha, J.-Y., Jung, J.-E., Chang, B.-C., Kwon, H.-J., Lee, B.-R., Kim, D.-Y., Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-κB inhibition. J. Ethnopharmacol. 136 (2011), 414–421, 10.1016/j.jep.2010.07.026.
82. [82] Liu, L., Shang, Y., Li, M., Han, X., Wang, J., Wang, J., Curcumin ameliorates asthmatic airway inflammation by activating nuclear factor-E2-related factor 2/haem oxygenase (HO)-1 signalling pathway. Clin. Exp. Pharmacol. Physiol. 42 (2015), 520–529, 10.1111/1440-1681.12384.
83. [83] Ma, C., Ma, Z., Fu, Q., Ma, S., Curcumin attenuates allergic airway inflammation by regulation of CD4 + CD25+ regulatory T cells (Tregs)/Th17 balance in ovalbumin-sensitized mice. Fitoterapia 87 (2013), 57–64, 10.1016/j.fitote.2013.02.014.
84. [84] Kobayashi, T., Hashimoto, S., Horie, T., Curcumin inhibition of Dermatophagoides farinea-induced interleukin-5 (IL-5) and granulocyte macrophage-colony stimulating factor (GM-CSF) production by lymphocytes from bronchial asthmatics. Biochem. Pharmacol. 54 (1997), 819–824.
85. [85] Moon, D.-O., Kim, M.-O., Lee, H.-J., Choi, Y.H., Park, Y.-M., Heo, M.-S., Kim, G.-Y., Curcumin attenuates ovalbumin-induced airway inflammation by regulating nitric oxide. Biochem. Biophys. Res. Commun. 375 (2008), 275–279, 10.1016/j.bbrc.2008.08.025.
86. [86] Barnes, P.J., Nitric oxide and airway disease. Ann. Med. 27 (1995), 389–393, 10.3109/07853899509002592.
87. [87] Guo, X., Zhou, M., Ren, L., Yang, M., Huang, S., Xu, W., Small interfering RNA-mediated knockdown of Notch1 in lung. Chin. Med. J. (Engl.) 122 (2009), 2647–2651.
88. [88] Chong, L., Zhang, W., Nie, Y., Yu, G., Liu, L., Lin, L., Wen, S., Zhu, L., Li, C., Protective effect of curcumin on acute airway inflammation of allergic asthma in mice through Notch1–GATA3 signaling pathway. Inflammation 37 (2014), 1476–1485, 10.1007/s10753-014-9873-6.
89. [89] Karaman, M., Firinci, F., Cilaker, S., Uysal, P., Tugyan, K., Yilmaz, O., Uzuner, N., Karaman, O., Anti-inflammatory effects of curcumin in a murine model of chronic asthma. Allergol. Immunopathol. (Madr.) 40 (2012), 210–214, 10.1016/j.aller.2011.04.006.
90. [90] Zeng, X., Cheng, Y., Qu, Y., Xu, J., Han, Z., Zhang, T., Curcumin inhibits the proliferation of airway smooth muscle cells in vitro and in vivo. Int. J. Mol. Med. 32 (2013), 629–636, 10.3892/ijmm.2013.1425.
91. [91] Kim, D.H., Phillips, J.F., Lockey, R.F., Oral curcumin supplementation in patients with atopic asthma. Allergy Rhinol. 2 (2011), e51–e53, 10.2500/ar.2011.2.0016.
92. [92] Abidi, A., Gupta, S., Agarwal, M., Bhalla, H.L., Saluja, M., Evaluation of efficacy of curcumin as an add-on therapy in patients of bronchial asthma. J. Clin. Diagn. Res. JCDR 8 (2014), HC19–HC24, 10.7860/JCDR/2014/9273.4705.
93. [93] Dempsey, O.J., Kerr, K.M., Gomersall, L., Remmen, H., Currie, G.P., Idiopathic pulmonary fibrosis: an update, QJM Mon. J. Assoc. Phys. 99 (2006), 643–654, 10.1093/qjmed/hcl098.
94. [94] Chambers, R.C., Role of coagulation cascade proteases in lung repair and fibrosis. Eur. Respir. J. 44:Suppl (2003), 33s–35s.
95. [95] Corbel, M., Belleguic, C., Boichot, E., Lagente, V., Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol. Toxicol. 18 (2002), 51–61.
96. [96] McKeown, S., Richter, A.G., O'Kane, C., McAuley, D.F., Thickett, D.R., MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur. Respir. J. 33 (2009), 77–84, 10.1183/09031936.00060708.
97. [97] Büttner, C., Skupin, A., Reimann, T., Rieber, E.P., Unteregger, G., Geyer, P., Frank, K.H., Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: macrophages as a prominent source of interleukin-4. Am. J. Respir. Cell Mol. Biol. 17 (1997), 315–325, 10.1165/ajrcmb.17.3.2279.
98. [98] Song, E., Ouyang, N., Hörbelt, M., Antus, B., Wang, M., Exton, M.S., Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell. Immunol. 204 (2000), 19–28, 10.1006/cimm.2000.1687.
99. [99] Malavia, N.K., Mih, J.D., Raub, C.B., Dinh, B.T., George, S.C., IL-13 induces a bronchial epithelial phenotype that is profibrotic. Respir. Res., 9, 2008, 27, 10.1186/1465-9921-9-27.
100. [100] Smith, M.R., Gangireddy, S.R., Narala, V.R., Hogaboam, C.M., Standiford, T.J., Christensen, P.J., Kondapi, A.K., Reddy, R.C., Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 298 (2010), L616–L625, 10.1152/ajplung.00002.2009.
101. [101] Xu, M., Deng, B., Chow, Y.-L., Zhao, Z.-Z., Hu, B., Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone. J. Ethnopharmacol. 112 (2007), 292–299, 10.1016/j.jep.2007.03.011.
102. [102] Punithavathi, D., Venkatesan, N., Babu, M., Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br. J. Pharmacol. 131 (2000), 169–172, 10.1038/sj.bjp.0703578.
103. [103] Hamdy, M.A., El-Maraghy, S.A., Kortam, M.A.E.A., Modulatory effects of curcumin and green tea extract against experimentally induced pulmonary fibrosis: a comparison with N-acetyl cysteine. J. Biochem. Mol. Toxicol. 26 (2012), 461–468, 10.1002/jbt.21447.
104. [104] Cho, Y.J., Yi, C.O., Jeon, B.T., Jeong, Y.Y., Kang, G.M., Lee, J.E., Roh, G.S., Lee, J.D., Curcumin attenuates radiation-induced inflammation and fibrosis in rat lungs. Korean J. Physiol. Pharmacol. 17 (2013), 267–274, 10.4196/kjpp.2013.17.4.267.
105. [105] Thresiamma, K.C., George, J., Kuttan, R., Protective effect of curcumin, ellagic acid and bixin on radiation induced toxicity. Indian J. Exp. Biol. 34 (1996), 845–847.
106. [106] Lee, J.C., Kinniry, P.A., Arguiri, E., Serota, M., Kanterakis, S., Chatterjee, S., Solomides, C.C., Javvadi, P., Koumenis, C., Cengel, K.A., Christofidou-Solomidou, M., Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat. Res. 173 (2010), 590–601, 10.1667/RR1522.1.
107. [107] Avasarala, S., Zhang, F., Liu, G., Wang, R., London, S.D., London, L., Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. PLoS One, 8, 2013, e57285, 10.1371/journal.pone.0057285.
108. [108] Li, W., Kornmark, L., Jonasson, L., Forssell, C., Yuan, X.-M., Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis 202 (2009), 92–102, 10.1016/j.atherosclerosis.2008.03.027.
109. [109] Zhang, D., Leung, N., Weber, E., Saftig, P., Brömme, D., The effect of cathepsin K deficiency on airway development and TGF-β1 degradation. Respir. Res., 12, 2011, 72, 10.1186/1465-9921-12-72.
110. [110] Welsh, M.J., Smith, A.E., Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73 (1993), 1251–1254.
111. [111] Mathews, C.J., Tabcharani, J.A., Chang, X.B., Jensen, T.J., Riordan, J.R., Hanrahan, J.W., Dibasic protein kinase A sites regulate bursting rate and nucleotide sensitivity of the cystic fibrosis transmembrane conductance regulator chloride channel. J. Physiol. 508:Pt. 2 (1998), 365–377.
112. [112] Sheppard, D.N., Welsh, M.J., Structure and function of the CFTR chloride channel. Physiol. Rev. 79 (1999), S23–S45.
113. [113] Davis, P.B., Cystic fibrosis. Pediatr. Rev. Am. Acad. Pediatr. 22 (2001), 257–264.
114. [114] Cheng, S.H., Gregory, R.J., Marshall, J., Paul, S., Souza, D.W., White, G.A., O'Riordan, C.R., Smith, A.E., Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63 (1990), 827–834.
115. [115] Gregory, R.J., Rich, D.P., Cheng, S.H., Souza, D.W., Paul, S., Manavalan, P., Anderson, M.P., Welsh, M.J., Smith, A.E., Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2. Mol. Cell. Biol. 11 (1991), 3886–3893.
116. [116] Quint, A., Lerer, I., Sagi, M., Abeliovich, D., Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. Am. J. Med. Genet. A. 136 (2005), 246–248, 10.1002/ajmg.a.30823.
117. [117] Saiman, L., Microbiology of early CF lung disease. Paediatr. Respir. Rev. 5:Suppl. A (2004), S367–S369.
118. [118] Soferman, R., Immunopathophysiologic mechanisms of cystic fibrosis lung disease. Isr. Med. Assoc. J. IMAJ 8 (2006), 44–48.
119. [119] Jacquot, J., Tabary, O., Clement, A., Hyperinflammation in airways of cystic fibrosis patients: what's new?. Expert Rev. Mol. Diagn. 8 (2008), 359–363, 10.1586/14737159.8.4.359.
120. [120] Pind, S., Riordan, J.R., Williams, D.B., Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269 (1994), 12784–12788.
121. [121] Egan, M.E., Pearson, M., Weiner, S.A., Rajendran, V., Rubin, D., Glöckner-Pagel, J., Canny, S., Du, K., Lukacs, G.L., Caplan, M.J., Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304 (2004), 600–602, 10.1126/science.1093941.
122. [122] Dragomir, A., Björstad, J., Hjelte, L., Roomans, G.M., Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem. Biophys. Res. Commun. 322 (2004), 447–451, 10.1016/j.bbrc.2004.07.146.
123. [123] Song, Y., Sonawane, N.D., Salinas, D., Qian, L., Pedemonte, N., Galietta, L.J.V., Verkman, A.S., Evidence against the rescue of defective ΔF508-CFTR cellular processing by curcumin in cell culture and mouse models. J. Biol. Chem. 279 (2004), 40629–40633, 10.1074/jbc.M407308200.
124. [124] Berger, A.L., Randak, C.O., Ostedgaard, L.S., Karp, P.H., Vermeer, D.W., Welsh, M.J., Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl–Channel activity. J. Biol. Chem. 280 (2005), 5221–5226, 10.1074/jbc.M412972200.
125. [125] Wang, W., Bernard, K., Li, G., Kirk, K.L., Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J. Biol. Chem. 282 (2007), 4533–4544, 10.1074/jbc.M609942200.
126. [126] Yu, Y.-C., Miki, H., Nakamura, Y., Hanyuda, A., Matsuzaki, Y., Abe, Y., Yasui, M., Tanaka, K., Hwang, T.-C., Bompadre, S.G., Sohma, Y., Curcumin and genistein additively potentiate G551D-CFTR. J. Cyst. Fibros. 10 (2011), 243–252, 10.1016/j.jcf.2011.03.001.
127. [127] Bernard, K., Wang, W., Narlawar, R., Schmidt, B., Kirk, K.L., Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms. J. Biol. Chem. 284 (2009), 30754–30765, 10.1074/jbc.M109.056010.
128. [128] Lipecka, J., Norez, C., Bensalem, N., Baudouin-Legros, M., Planelles, G., Becq, F., Edelman, A., Davezac, N., Rescue of ΔF508-CFTR (Cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network. J. Pharmacol. Exp. Ther. 317 (2006), 500–505, 10.1124/jpet.105.097667.
129. [129] Davezac, N., Tondelier, D., Lipecka, J., Fanen, P., Demaugre, F., Debski, J., Dadlez, M., Schrattenholz, A., Cahill, M.A., Edelman, A., Global proteomic approach unmasks involvement of keratins 8 and 18 in the delivery of cystic fibrosis transmembrane conductance regulator (CFTR)/deltaF508-CFTR to the plasma membrane. Proteomics 4 (2004), 3833–3844, 10.1002/pmic.200400850.
130. [130] Wang, G., Interplay between inhibitory ferric and stimulatory curcumin regulates phosphorylation-Dependent human cystic fibrosis transmembrane conductance regulator and (F508 activity. Biochemistry (Mosc.) 54 (2015), 1558–1566, 10.1021/bi501318h.
131. [131] Wang, G., Molecular basis for Fe(III)-independent curcumin potentiation of cystic fibrosis transmembrane conductance regulator activity. Biochemistry (Mosc.) 54 (2015), 2828–2840, 10.1021/acs.biochem.5b00219.
132. [132] Ware, L.B., Matthay, M.A., The acute respiratory distress syndrome. N. Engl. J. Med. 342 (2000), 1334–1349, 10.1056/NEJM200005043421806.
133. [133] Schreiber, M.P., Chan, C.M., Shorr, A.F., Bacteremia in Staphylococcus aureus pneumonia: outcomes and epidemiology. J. Crit. Care 26 (2011), 395–401, 10.1016/j.jcrc.2010.09.002.
134. [134] Zhao, W., Gan, X., Su, G., Wanling, G., Li, S., Hei, Z., Yang, C., Wang, H., The interaction between oxidative stress and mast cell activation plays a role in acute lung injuries induced by intestinal ischemia-reperfusion. J. Surg. Res. 187 (2014), 542–552, 10.1016/j.jss.2013.10.033.
135. [135] Su, C.-F., Kao, S.J., Chen, H.I., Acute respiratory distress syndrome and lung injury: pathogenetic mechanism and therapeutic implication. World J. Crit. Care Med. 1 (2012), 50–60, 10.5492/wjccm.v1.i2.50.
136. [136] Johnson, E.R., Matthay, M.A., Acute lung injury: epidemiology, pathogenesis, and treatment. J. Aerosol Med. Pulm. Drug Deliv. 23 (2010), 243–252, 10.1089/jamp.2009.0775.
137. [137] Goodman, R.B., Pugin, J., Lee, J.S., Matthay, M.A., Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev. 14 (2003), 523–535.
138. [138] Grommes, J., Soehnlein, O., Contribution of neutrophils to acute lung injury. Mol. Med. Camb. Mass. 17 (2011), 293–307, 10.2119/molmed.2010.00138.
139. [139] Chabot, F., Mitchell, J.A., Gutteridge, J.M., Evans, T.W., Reactive oxygen species in acute lung injury. Eur. Respir. J. 11 (1998), 745–757.
140. [140] Cheng, I.W., Ware, L.B., Greene, K.E., Nuckton, T.J., Eisner, M.D., Matthay, M.A., Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit. Care Med. 31 (2003), 20–27, 10.1097/01.CCM.0000045028.46623.C2.
141. [141] Leth-Larsen, R., Nordenbaek, C., Tornoe, I., Moeller, V., Schlosser, A., Koch, C., Teisner, B., Junker, P., Holmskov, U., Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia. Clin. Immunol. Orlando Fla. 108 (2003), 29–37.
142. [142] Fan, Z., Yao, J., Li, Y., Hu, X., Shao, H., Tian, X., Anti-inflammatory and antioxidant effects of curcumin on acute lung injury in a rodent model of intestinal ischemia reperfusion by inhibiting the pathway of NF-Kb. Int. J. Clin. Exp. Pathol. 8 (2015), 3451–3459.
143. [143] Guzel, A., Kanter, M., Guzel, A., Yucel, A.F., Erboga, M., Protective effect of curcumin on acute lung injury induced by intestinal ischaemia/reperfusion. Toxicol. Ind. Health 29 (2013), 633–642, 10.1177/0748233711430984.
144. [144] Dong, Z.W., Chen, J., Ruan, Y.C., Zhou, T., Chen, Y., Chen, Y., Tsang, L.L., Chan, H.C., Peng, Y.Z., CFTR-regulated MAPK/NF-κB signaling in pulmonary inflammation in thermal inhalation injury. Sci. Rep., 5, 2015, 15946, 10.1038/srep15946.
145. [145] Bansal, S., Chhibber, S., Curcumin alone and in combination with augmentin protects against pulmonary inflammation and acute lung injury generated during Klebsiella pneumoniae B5055-induced lung infection in BALB/c mice. J. Med. Microbiol. 59 (2010), 429–437, 10.1099/jmm.0.016873-0.
146. [146] Kim, J., Jeong, S.-W., Quan, H., Jeong, C.-W., Choi, J.-I., Bae, H.-B., Effect of curcumin (Curcuma longa extract) on LPS-induced acute lung injury is mediated by the activation of AMPK. J. Anesth. 30 (2016), 100–108, 10.1007/s00540-015-2073-1.
147. [147] Kumari, A., Tyagi, N., Dash, D., Singh, R., Intranasal curcumin ameliorates lipopolysaccharide-Induced acute lung injury in mice. Inflammation 38 (2015), 1103–1112, 10.1007/s10753-014-0076-y.
148. [148] Xu, F., Lin, S., Yang, Y., Guo, R., Cao, J., Liu, Q., The effect of curcumin on sepsis-induced acute lung injury in a rat model through the inhibition of the TGF-β1/SMAD3 pathway. Int. Immunopharmacol. 16 (2013), 1–6, 10.1016/j.intimp.2013.03.014.
149. [149] Gunaydın, M., Guzel, A., Guzel, A., Alacam, H., Salis, O., Murat, N., Gacar, A., Guvenc, T., The effect of curcumin on lung injuries in a rat model induced by aspirating gastrointestinal decontamination agents. J. Pediatr. Surg. 47 (2012), 1669–1676, 10.1016/j.jpedsurg.2012.01.076.
150. [150] Guzel, A., Kanter, M., Aksu, B., Basaran, U.N., Yalçin, O., Guzel, A., Uzun, H., Konukoğlu, D., Karasalihoglu, S., Preventive effects of curcumin on different aspiration material-induced lung injury in rats. Pediatr. Surg. Int. 25 (2009), 83–92, 10.1007/s00383-008-2282-x.
151. [151] Xiao, X., Yang, M., Sun, D., Sun, S., Curcumin protects against sepsis-induced acute lung injury in rats. J. Surg. Res. 176 (2012), e31–39, 10.1016/j.jss.2011.11.1032.
152. [152] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012, Ca. Cancer J. Clin. 62 (2012), 10–29, 10.3322/caac.20138.
153. [153] Mountain, C.F., Lukeman, J.M., Hammar, S.P., Chamberlain, D.W., Coulson, W.F., Page, D.L., Victor, T.A., Weiland, L.H., Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J. Surg. Oncol. 35 (1987), 147–156.
154. [154] Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
155. [155] Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
156. [156] Nana-Sinkam, S.P., Geraci, M.W., MicroRNA in lung cancer. J. Thorac. Oncol. 1 (2006), 929–931.
157. [157] Li, M., Zhang, Q., Wu, L., Jia, C., Shi, F., Li, S., Peng, A., Zhang, G., Song, X., Wang, C., Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer. Oncol. Rep. 31 (2014), 1961–1967, 10.3892/or.2014.3029.
158. [158] Herman, J.G., Baylin, S.B., Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003), 2042–2054, 10.1056/NEJMra023075.
159. [159] Virmani, A.K., Rathi, A., Zöchbauer-Müller, S., Sacchi, N., Fukuyama, Y., Bryant, D., Maitra, A., Heda, S., Fong, K.M., Thunnissen, F., Minna, J.D., Gazdar, A.F., Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 92 (2000), 1303–1307.
160. [160] Baylin, S.B., Esteller, M., Rountree, M.R., Bachman, K.E., Schuebel, K., Herman, J.G., Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10 (2001), 687–692.
161. [161] el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., Vogelstein, B., WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993), 817–825.
162. [162] Duffy, M.J., Synnott, N.C., McGowan, P.M., Crown, J., O'Connor, D., Gallagher, W.M., p53 as a target for the treatment of cancer. Cancer Treat. Rev. 40 (2014), 1153–1160, 10.1016/j.ctrv.2014.10.004.
163. [163] Harada, D., Takigawa, N., Kiura, K., The role of STAT3 in non-small cell lung cancer. Cancers 6 (2014), 708–722, 10.3390/cancers6020708.
164. [164] Sansone, P., Bromberg, J., Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 30 (2012), 1005–1014, 10.1200/JCO.2010.31.8907.
165. [165] Bacac, M., Stamenkovic, I., Metastatic cancer cell. Annu. Rev. Pathol. 3 (2008), 221–247, 10.1146/annurev.pathmechdis.3.121806.151523.
166. [166] Shin, S.Y., Kim, J.H., Baker, A., Lim, Y., Lee, Y.H., Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor alpha. Mol. Cancer Res. MCR 8 (2010), 507–519, 10.1158/1541-7786.MCR-09-0454.
167. [167] Chen, Q.-Y., Xu, L.-Q., Jiao, D.-M., Yao, Q.-H., Wang, Y.-Y., Hu, H.-Z., Wu, Y.-Q., Song, J., Yan, J., Wu, L.-J., Silencing of Rac1 modifies lung cancer cell migration, invasion and actin cytoskeleton rearrangements and enhances chemosensitivity to antitumor drugs. Int. J. Mol. Med. 28 (2011), 769–776, 10.3892/ijmm.2011.775.
168. [168] Koning, C.C., Wouterse, S.J., Daams, J.G., Uitterhoeve, L.L., van den Heuvel, M.M., Belderbos, J.S., Toxicity of concurrent radiochemotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin. Lung Cancer 14 (2013), 481–487, 10.1016/j.cllc.2013.03.002.
169. [169] Zhang, J., Du, Y., Wu, C., Ren, X., Ti, X., Shi, J., Zhao, F., Yin, H., Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol. Rep. 24 (2010), 1217–1223.
170. [170] Jin, H., Qiao, F., Wang, Y., Xu, Y., Shang, Y., Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3 K/Akt signaling pathway. Oncol. Rep. 34 (2015), 2782–2789, 10.3892/or.2015.4258.
171. [171] Ye, M., Zhang, J., Zhang, J., Miao, Q., Yao, L., Zhang, J., Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer Lett. 357 (2015), 196–205, 10.1016/j.canlet.2014.11.028.
172. [172] Atsumi, T., Tonosaki, K., Fujisawa, S., Comparative cytotoxicity and ROS generation by curcumin and tetrahydrocurcumin following visible-light irradiation or treatment with horseradish peroxidase. Anticancer Res. 27 (2007), 363–371.
173. [173] Hosseinzadehdehkordi, M., Adelinik, A., Tashakor, A., Dual effect of curcumin targets reactive oxygen species, adenosine triphosphate contents and intermediate steps of mitochondria-mediated apoptosis in lung cancer cell lines. Eur. J. Pharmacol. 769 (2015), 203–210, 10.1016/j.ejphar.2015.11.019.
174. [174] Yang, C.-L., Liu, Y.-Y., Ma, Y.-G., Xue, Y.-X., Liu, D.-G., Ren, Y., Liu, X.-B., Li, Y., Li, Z., Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One, 7, 2012, e37960, 10.1371/journal.pone.0037960.
175. [175] Alexandrow, M.G., Song, L.J., Altiok, S., Gray, J., Haura, E.B., Kumar, N.B., Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur. J. Cancer Prev. 21 (2012), 407–412, 10.1097/CEJ.0b013e32834ef194.
176. [176] Wu, L., Guo, L., Liang, Y., Liu, X., Jiang, L., Wang, L., Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway. Oncol. Rep. 34 (2015), 3311–3317, 10.3892/or.2015.4279.
177. [177] Chen, K., Huang, Y., Chen, J., Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol. Sin. 34 (2013), 732–740, 10.1038/aps.2013.27.
178. [178] Kops, G.J.P.L., Medema, R.H., Glassford, J., Essers, M.A.G., Dijkers, P.F., Coffer, P.J., Lam, E.W.-F., Burgering, B.M.T., Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol. Cell. Biol 22 (2002), 2025–2036.
179. [179] Li, Z.-C., Zhang, L.-M., Wang, H.-B., Ma, J.-X., Sun, J.-Z., Curcumin inhibits lung cancer progression and metastasis through induction of FOXO1. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 35 (2014), 111–116, 10.1007/s13277-013-1013-7.
180. [180] Jiang, A., Wang, X., Shan, X., Li, Y., Wang, P., Jiang, P., Feng, Q., Curcumin reactivates silenced tumor suppressor gene RARβ by reducing DNA methylation. Phytother. Res. PTR 29 (2015), 1237–1245, 10.1002/ptr.5373.
181. [181] Chen, Q., Jiao, D., Wang, L., Wang, L., Hu, H., Song, J., Yan, J., Wu, L., Shi, J., Curcumin inhibits proliferation-migration of NSCLC by steering crosstalk between a Wnt signaling pathway and an adherens junction via EGR-1. Mol. Biosyst. 11 (2015), 859–868, 10.1039/c4mb00336e.
182. [182] Fan, Z., Duan, X., Cai, H., Wang, L., Li, M., Qu, J., Li, W., Wang, Y., Wang, J., Curcumin inhibits the invasion of lung cancer cells by modulating the PKCα/Nox-2/ROS/ATF-2/MMP-9 signaling pathway. Oncol. Rep. 34 (2015), 691–698, 10.3892/or.2015.4044.
183. [183] Chen, Q., Zheng, Y., Jiao, D., Chen, F., Hu, H., Wu, Y., Song, J., Yan, J., Wu, L., Lv, G., Curcumin inhibits lung cancer cell migration and invasion through Rac1-dependent signaling pathway. J. Nutr. Biochem. 25 (2014), 177–185, 10.1016/j.jnutbio.2013.10.004.
184. [184] Kerenidi, T., Lada, M., Tsaroucha, A., Georgoulias, P., Mystridou, P., Gourgoulianis, K.I., Clinical significance of serum adipokines levels in lung cancer. Med. Oncol. Northwood Lond. Engl., 30, 2013, 507, 10.1007/s12032-013-0507-x.
185. [185] Tsai, J.-R., Liu, P.-L., Chen, Y.-H., Chou, S.-H., Cheng, Y.-J., Hwang, J.-J., Chong, I.-W., Curcumin inhibits non-Small cell lung cancer cells metastasis through the adiponectin/NF-(b/MMPs signaling pathway. PLoS One, 10, 2015, e0144462, 10.1371/journal.pone.0144462.
186. [186] Kartalou, M., Essigmann, J.M., Mechanisms of resistance to cisplatin. Mutat. Res. 478 (2001), 23–43.
187. [187] Chen, P., Li, J., Jiang, H.-G., Lan, T., Chen, Y.-C., Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 36 (2015), 3591–3599, 10.1007/s13277-014-2996-4.
188. [188] Ye, M.-X., Zhao, Y.-L., Li, Y., Miao, Q., Li, Z.-K., Ren, X.-L., Song, L.-Q., Yin, H., Zhang, J., Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms. Phytomed. Int. J. Phytother. Phytopharm. 19 (2012), 779–787, 10.1016/j.phymed.2012.03.005.
189. [189] Baharuddin, P., Satar, N., Fakiruddin, K., Zakaria, N., Lim, M., Yusoff, N., Zakaria, Z., Yahaya, B., Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines. Oncol. Rep., 2015, 10.3892/or.2015.4371.
190. [190] Li, S., Liu, Z., Zhu, F., Fan, X., Wu, X., Zhao, H., Jiang, L., Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Oncol. Res. 21 (2013), 137–144, 10.3727/096504013X13832473330032.
191. [191] Yin, H., Guo, R., Xu, Y., Zheng, Y., Hou, Z., Dai, X., Zhang, Z., Zheng, D., Xu, H.’e, Synergistic antitumor efficiency of docetaxel and curcumin against lung cancer. Acta Biochim. Biophys. Sin. 44 (2012), 147–153, 10.1093/abbs/gmr106.
192. [192] Lee, J.-Y., Lee, Y.-M., Chang, G.-C., Yu, S.-L., Hsieh, W.-Y., Chen, J.J.W., Chen, H.-W., Yang, P.-C., Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS One, 6, 2011, e23756, 10.1371/journal.pone.0023756.
193. [193] Ting, C.-Y., Wang, H.-E., Yu, C.-C., Liu, H.-C., Liu, Y.-C., Chiang, I.-T., Curcumin triggers DNA damage and inhibits expression of DNA repair proteins in human lung cancer cells. Anticancer Res. 35 (2015), 3867–3873.
194. [194] Sandur, S.K., Pandey, M.K., Sung, B., Ahn, K.S., Murakami, A., Sethi, G., Limtrakul, P., Badmaev, V., Aggarwal, B.B., Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 28 (2007), 1765–1773, 10.1093/carcin/bgm123.
195. [195] Pan, M.H., Huang, T.M., Lin, J.K., Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. Biol. Fate Chem. 27 (1999), 486–494.
196. [196] Wahlström, B., Blennow, G., A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol. (Copenh.) 43 (1978), 86–92.
197. [197] Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., Srinivas, P.S., Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64 (1998), 353–356, 10.1055/s-2006-957450.
198. [198] Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., Maitra, A., Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. J. Nanobiotechnol., 5, 2007, 3, 10.1186/1477-3155-5-3.
199. [199] Maiti, K., Mukherjee, K., Gantait, A., Saha, B.P., Mukherjee, P.K., Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 330 (2007), 155–163, 10.1016/j.ijpharm.2006.09.025.
200. [200] Marczylo, T.H., Verschoyle, R.D., Cooke, D.N., Morazzoni, P., Steward, W.P., Gescher, A.J., Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol. 60 (2007), 171–177, 10.1007/s00280-006-0355-x.
201. [201] Wang, W., Zhu, R., Xie, Q., Li, A., Xiao, Y., Li, K., Liu, H., Cui, D., Chen, Y., Wang, S., Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int. J. Nanomed. 7 (2012), 3667–3677, 10.2147/IJN.S30428.